The overall goal of my lab is to investigate targets and pathways implicated or hypothesized to be important in the pathogenesis and continued progression of progressive multiple sclerosis (MS), with some natural overlap in other neurodegenerative diseases. Our work includes both discovery research in specific neuroinflammatory and neurodegenerative pathways, and the related development and application of new disease models for specific aspects of progressive MS and neurodegenerative disorders. We utilize both in vivo and in vitro methodologies in our research and actively collaborate with top-tier academic labs that share similar interests. We also support a number of ongoing remyelination and neuroprotection projects at Biogen.

Prior to joining Biogen, I worked at the confluence of immunology and neuroinflammation at Elan Pharmaceuticals, where I contributed at the bench and as an in vivo pharmacology group leader for over eight years. During that time, I led research project teams and external collaborations for several MS early-discovery targets, investigated the preclinical pharmacology and mechanism of action for anti-VLA-4 antibody TYSABRI® (natalizumab), and established a number of in-house autoimmune models for MS, inflammatory bowel disease and rheumatoid arthritis to validate new targets and support small molecules in development. My earlier graduate research was conducted in the laboratory of Prof. Mike Bevan at University of Washington in Seattle, and my postdoctoral training was in the lab of Prof. Paul Allen at Washington University in St. Louis.


  • Postdoctoral Fellow, Laboratory of Paul M. Allen, Ph.D., Department of Pathology and Immunology, Washington University, St. Louis, MO, 2003
  • Ph.D., Immunology, Laboratory of Michael J. Bevan, Ph.D. F.R.S., Department of Immunology, University of Washington, Seattle, WA, 1997

Selected Publications

See more scientists